2021
An emulated target trial analysis based on Medicare data suggested non-inferiority of Dabigatran versus Rivaroxaban
Mei H, Wang J, Ma S. An emulated target trial analysis based on Medicare data suggested non-inferiority of Dabigatran versus Rivaroxaban. Journal Of Clinical Epidemiology 2021, 139: 28-37. PMID: 34271110, DOI: 10.1016/j.jclinepi.2021.07.001.Peer-Reviewed Original ResearchConceptsNon-valvular atrial fibrillation patientsSafety of rivaroxabanAtrial fibrillation patientsMultiple chronic conditionsInclusion/exclusion criteriaTrial analysisMajor bleedingOral anticoagulantsThromboembolic eventsFibrillation patientsTreatment regimensChronic conditionsClinical trialsMedicare patientsDabigatranExclusion criteriaMedicare dataRivaroxabanStudy designRelative efficacyIndividual trialsTrialsPatientsStrokePrimary event
2020
Evaluation of Survival Outcomes of Endovascular Versus Open Aortic Repair for Abdominal Aortic Aneurysms with a Big Data Approach
Mei H, Xu Y, Wang J, Ma S. Evaluation of Survival Outcomes of Endovascular Versus Open Aortic Repair for Abdominal Aortic Aneurysms with a Big Data Approach. Entropy 2020, 22: 1349. PMID: 33265931, PMCID: PMC7759828, DOI: 10.3390/e22121349.Peer-Reviewed Original ResearchEndovascular aortic repairAbdominal aortic aneurysmAortic repairSurvival outcomesAortic aneurysmClinical trialsOpen aortic repairLong-term mortalityInclusion/exclusion criteriaCritical clinical problemGreat clinical significanceAbdominal aortaClinical significanceExclusion criteriaSurvival advantageClinical problemMedicare dataLocalized enlargementAneurysmsOARsTrialsRepairOutcomesPatientsRAAA